Salvage Chemoimmunotherapy With Inotuzumab Ozogamicin Combined With Mini–Hyper-CVD for Patients With Relapsed or Refractory Philadelphia Chromosome–Negative Acute Lymphoblastic LeukemiaElias Jabbour, Hagop M. Kantarjian, Nitin Jain et al.|JAMA Oncology|2017Cited by 156
Chemoimmunotherapy with inotuzumab ozogamicin combined with mini‐hyper‐CVD, with or without blinatumomab, is highly effective in patients with Philadelphia chromosome–negative acute lymphoblastic leukemia in first salvageElias Jabbour, Hagop M. Kantarjian, Koji Sasaki et al.|Cancer|2018Cited by 110
Hyper-CVAD regimen in combination with ofatumumab as frontline therapy for adults with Philadelphia chromosome-negative B-cell acute lymphoblastic leukaemia: a single-arm, phase 2 trialElias Jabbour, Hagop M. Kantarjian, Guillaume Richard‐Carpentier et al.|The Lancet Haematology|2020Cited by 64
Sequential Combination of Low-Intensity Chemotherapy (Mini-hyper-CVD) Plus Inotuzumab Ozogamicin with or without Blinatumomab in Patients with Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia (ALL): A Phase 2 TrialKoji Sasaki, Elias Jabbour, Hagop M. Kantarjian et al.|Blood|2018Cited by 17